december 8, 2022

Talabostat mesylate

Talabostat mesylate 

To Order Contact us: bjorn@lembcke.dk

Talabostat isomer mesylate

HY-13233B 10mg
EUR 666

Talabostat

HY-13233 50mg
EUR 734.4

Camostat . mesylate

10-017 50 mg
EUR 410.64
Description: Camostat is an orally bioavailable trypsin-like protease inhibitor known to inhibit trypsin and various inflammatory proteases including plasmin, kallikrein and thrombin. Camostat has been shown to inhibit the production of TNF-α and monocyte chemoattractant protein-1 by monocytes and to disrupt proliferation of pancreatic stellate cells in a rat model of pancreatic fibrosis. Protease regulation via camostat has also been reported to reversibly inhibit epithelial sodium channel function in human airway epithelial cell models. It is used in the treatment of some forms of cancer and is also effective against some viral infections (such as SARS, MERS or influenza), as well as inhibiting fibrosis in liver or kidney disease or pancreatitis. It suppresses pancreatitis-induced pain in rats following oral administration and is used to treat pancreatitis and reflux esophagitis after gastrectomy. It is an inhibitor of the enzyme transmembrane serine protease TMPRSS2 and partially blocks infection by SARS-CoV and human coronavirus NL63 in HeLa cells and entry of SARS-CoV2 (COVID-19) into lung cells in vitro.

Imatinib . mesylate

10-028 250 mg
EUR 471.12
Description: Imatinib mesylate is a multitarget tyrosine kinase inhibitor with antineoplastic activity. It is a potent and selective inhibitor of the kinases Bcr-Abl (IC50 = 38 nM), PDGFR and c-Kit, which are encoded by the bcr-abl oncogene as well as receptor tyrosine kinases encoded by c-Kit and platelet-derived growth factor receptor (PDGFR) oncogenes, which is useful in vitro and in vivo. Imatinib inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit and the proliferation of Bcr-Abl-dependent R10 cells and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner. Formulations containing imatinib have been used in the treatment of various cancers. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis and myelodysplastic syndrome. Abelson (Abl) kinase inhibitors have been shown to inhibit replication of Ebola virus, coxsackievirus and vaccinia virus, but at different points of the virus life cycle. Imatinib inhibits replication of SARS-CoV and MERS-CoV in vitro by a novel mechanism of blocking coronavirus virion fusion with the endosomal membrane. Abl is also a potential drug target of SARS-CoV-2 and can possible inhibit the spread of COVID-19.

Nafamostat . mesylate

10-031 50 mg
EUR 440.88
Description: Nafamostat mesylate is a cell permeable broad spectrum potent and reversible synthetic serine protease inhibitor and kallikrein inhibitor in vitro and in vivo. It inhibits trypsin (Ki=15nM), tryptase (Ki=95.3pM) and additional proteases in the coagulation cascade including thrombin (Ki=0.84µM). Nafamostat mesylate is a short-acting anticoagulant with anti-inflammatory, anticancer and antiviral properties. As a potential anticancer agent, it blocks canonical NF-κB signaling, targets TNFR1-stimulated cleavage of caspase families and the tryptase of mast cells to improve therapeutic outcome and to ameliorate cancer therapy resistance and avoid immune resistance. It has been shown to reduce eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma. Inhibits the demethylase activity of the fat mass and obesity-associated protein (FTO). As antiviral agent, it inhibits Ebola virus, MERS-CoV and SARS-CoV-2 infection in vitro and potentially the spread of COVID-19. Nafamostat mesylate inhibits TMPRSS2-dependent host cell entry of MERS-CoV. It is also an inhibitor of the enzyme transmembrane serine protease TMPRSS2 and blocks the entry of SARS-CoV-2 (COVID-19) into lung cells in vitro, with roughly 15-fold higher efficiency than Camostat mesylate (Prod. No. AG-CR1-3716), with an EC50 in the low nanomolar range.

Nelfinavir . mesylate

10-032 50 mg
EUR 486.24
Description: Nelfinavir is an orally bioavailable competitive inhibitor of the human immunodeficiency virus. It potently inhibits HIV-1 (Ki=2nM) and HIV-2 protease in vitro. HIV-1 protease is important for the replication of the virus within the cell and the release of mature viral particles from the infected cell. Formulations containing nelfinavir have been used in combination with HIV reverse transcriptase inhibitors for the treatment of AIDS. Nelfinavir shows other antimicrobial and antiviral activity. It inhibits maturation and export of the Herpes Simplex 1 virus and the Kaposi's Sarcoma virus, replication of SARS-CoV and also replication of SARS-CoV-2, cause for the epidemic COVID-19. Has potent anti-cancer activity against a broad selection fo cancer cell types. Shown to induce apoptosis, autophagy, cell cycle arrest and endoplasmic reticulum stress, which consequently leads to cancer cell death. Shown to inhibit the Akt/PKB signaling pathway. It acts as an antifibrotic agent and is used to treat pulmonary fibrosis in patients with systemic sclerosis (SSc) and reduces inflammation by activating protein phosphatase 2 (PP-2) and blocking mitogen-activated protein kinases (MAPK) signaling in macrophages.

Saquinavir . mesylate

10-044 50 mg
EUR 440.88
Description: Saquinavir is an antiretroviral inhibitor of the human immunodeficiency virus. It potently inhibits HIV-1 (Ki=0.12nM) and HIV-2 (Ki<0.1nM) protease in vitro. HIV-1 protease is important for the replication of the virus within the cell and the release of mature viral particles from the infected cell. Formulations containing saquinavir have been used in combination with other inhibitors for the treatment of AIDS. Saquinavir shows other antimicrobial and antiviral activity. Potential SARS-CoV-2 replication inhibitor, responsible for COVID-19. Shows anti-cancer activity. Shown to induce apoptosis, autophagy and endoplasmic reticulum stress, which consequently leads to cancer cell death. Anti-inflammatory agent. Blocks cathepsin V and thereby inhibits disulfide HMGB1-induced TLR4 activation and cytokine production.

Nafamostat Mesylate

1760-10
EUR 164.4

Nafamostat Mesylate

1760-50
EUR 424.8

Deferoxamine Mesylate

1883-1000
EUR 301.2

Deferoxamine Mesylate

1883-500
EUR 222

Rasagiline mesylate

2237-250
EUR 301.2

Rasagiline mesylate

2237-50
EUR 130.8

Bromocryptine (mesylate)

2916-250
EUR 392.4

Bromocryptine (mesylate)

2916-50
EUR 157.2

Doxazosin Mesylate

A2884-100 100 mg
EUR 199.2
Description: Doxazosin Mesylate is a selective, long-lasting antagonist of ?1-adrenergic receptor [1].Doxazosin Mesylate has been reported to potentiate contraction response to 5-HT in a dose-dependent manner [1].

Doxazosin Mesylate

A2884-5.1 10 mM (in 1mL DMSO)
EUR 170.4
Description: Doxazosin Mesylate is a selective, long-lasting antagonist of ?1-adrenergic receptor [1].Doxazosin Mesylate has been reported to potentiate contraction response to 5-HT in a dose-dependent manner [1].

Doxazosin Mesylate

A2884-50 50 mg
EUR 157.2
Description: Doxazosin Mesylate is a selective, long-lasting antagonist of ?1-adrenergic receptor [1].Doxazosin Mesylate has been reported to potentiate contraction response to 5-HT in a dose-dependent manner [1].

Ibutamoren Mesylate

A3481-10 10 mg
EUR 274.8
Description: Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue. Ibutamoren mesylate (MK-0677) stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor.

Ibutamoren Mesylate

A3481-25 25 mg
EUR 571.2
Description: Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue. Ibutamoren mesylate (MK-0677) stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor.

Ibutamoren Mesylate

A3481-5 5 mg
EUR 172.8
Description: Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue. Ibutamoren mesylate (MK-0677) stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor.

Ibutamoren Mesylate

A3481-50 50 mg
EUR 967.2
Description: Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue. Ibutamoren mesylate (MK-0677) stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor.

Gabexate mesylate

A4012-5 5 mg
EUR 129.6
Description: Gabexate mesylate is a non-antigenic synthetic inhibitor of trypsin-like serine proteinases with Ki values of 3.4nM and 180nM, respectively for human tryptase and bovine tryptase [1].

Gabexate mesylate

A4012-5.1 10 mM (in 1mL DMSO)
EUR 157.2
Description: Gabexate mesylate is a non-antigenic synthetic inhibitor of trypsin-like serine proteinases with Ki values of 3.4nM and 180nM, respectively for human tryptase and bovine tryptase [1].

Gabexate mesylate

A4012-50 50 mg
EUR 338.4
Description: Gabexate mesylate is a non-antigenic synthetic inhibitor of trypsin-like serine proteinases with Ki values of 3.4nM and 180nM, respectively for human tryptase and bovine tryptase [1].

Rasagiline Mesylate

A4366-5.1 10 mM (in 1mL DMSO)
EUR 135.6
Description: Rasagiline mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.

Rasagiline Mesylate

A4366-50 50 mg
EUR 153.6
Description: Rasagiline mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.

Safinamide Mesylate

A4368-10 10 mg
EUR 216
Description: Safinamide mesylate is the methanesulfonic acid form of its active component safinamide, a selective and reversible monoamine oxidase B (MAO-B) inhibitor with the value of 50% inhibition concentration IC50 of 98 nM.

Safinamide Mesylate

A4368-5.1 10 mM (in 1mL DMSO)
EUR 321.6
Description: Safinamide mesylate is the methanesulfonic acid form of its active component safinamide, a selective and reversible monoamine oxidase B (MAO-B) inhibitor with the value of 50% inhibition concentration IC50 of 98 nM.

Safinamide Mesylate

A4368-50 50 mg
EUR 559.2
Description: Safinamide mesylate is the methanesulfonic acid form of its active component safinamide, a selective and reversible monoamine oxidase B (MAO-B) inhibitor with the value of 50% inhibition concentration IC50 of 98 nM.

Safinamide Mesylate

A4368-500 500 mg
EUR 1131.6
Description: Safinamide mesylate is the methanesulfonic acid form of its active component safinamide, a selective and reversible monoamine oxidase B (MAO-B) inhibitor with the value of 50% inhibition concentration IC50 of 98 nM.

Imatinib mesylate

20-abx076675
  • EUR 460.80
  • EUR 292.80
  • 100 mg
  • 20 mg

Trovafloxacin mesylate

A8646-10 10 mg
EUR 266.4
Description: Fluoroquinolone antibiotic. Inhibits bacterial DNA topoisomerase IV and DNA gyrase and forms a stable quinolone-DNA complex with these enzymes which reversibly inhibits DNA synthesis. Displays potent activity against gram-positive and gram-negative bacter

Trovafloxacin mesylate

A8646-5 5 mg
EUR 174
Description: Fluoroquinolone antibiotic. Inhibits bacterial DNA topoisomerase IV and DNA gyrase and forms a stable quinolone-DNA complex with these enzymes which reversibly inhibits DNA synthesis. Displays potent activity against gram-positive and gram-negative bacter

Trovafloxacin mesylate

A8646-50 50 mg
EUR 1040.4
Description: Fluoroquinolone antibiotic. Inhibits bacterial DNA topoisomerase IV and DNA gyrase and forms a stable quinolone-DNA complex with these enzymes which reversibly inhibits DNA synthesis. Displays potent activity against gram-positive and gram-negative bacter

Flumatinib mesylate

A8691-5.1 10 mM (in 1mL DMSO)
EUR 297.6
Description: Flumatinib (HH-GV-678) ?a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFR? and c-Kit respectively.

Flumatinib mesylate

A8691-500 500 mg
EUR 277.2
Description: Flumatinib (HH-GV-678) ?a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFR? and c-Kit respectively.

Nelfinavir Mesylate

A3653-10 10 mg
EUR 151.2
Description: Nelfinavir Mesylate is a potent inhibitor of HIV-1 protease [1].HIV-1 protease is a constitutive enzyme that processes gag and gag-pol polyproteins for packaging into the nascent virion actively budding from a productively infected cell.

Nelfinavir Mesylate

A3653-5 5 mg
EUR 129.6
Description: Nelfinavir Mesylate is a potent inhibitor of HIV-1 protease [1].HIV-1 protease is a constitutive enzyme that processes gag and gag-pol polyproteins for packaging into the nascent virion actively budding from a productively infected cell.

Nelfinavir Mesylate

A3653-5.1 10 mM (in 1mL DMSO)
EUR 164.4
Description: Nelfinavir Mesylate is a potent inhibitor of HIV-1 protease [1].HIV-1 protease is a constitutive enzyme that processes gag and gag-pol polyproteins for packaging into the nascent virion actively budding from a productively infected cell.

Nelfinavir Mesylate

A3653-50 50 mg
EUR 393.6
Description: Nelfinavir Mesylate is a potent inhibitor of HIV-1 protease [1].HIV-1 protease is a constitutive enzyme that processes gag and gag-pol polyproteins for packaging into the nascent virion actively budding from a productively infected cell.

Saquinavir mesylate

A3791-10 10 mg
EUR 129.6
Description: Saquinavir is a potent inhibitor HIV protease with Ki value of 0.12 and < 0.1 nM for HIV-1 and HIV-2 protease[1].HIV protease is essential for release of mature viral and viral replication which is a retroviral aspartyl protease[2].

Saquinavir mesylate

A3791-200 200 mg
EUR 847.2
Description: Saquinavir is a potent inhibitor HIV protease with Ki value of 0.12 and < 0.1 nM for HIV-1 and HIV-2 protease[1].HIV protease is essential for release of mature viral and viral replication which is a retroviral aspartyl protease[2].

Saquinavir mesylate

A3791-25 25 mg
EUR 160.8
Description: Saquinavir is a potent inhibitor HIV protease with Ki value of 0.12 and < 0.1 nM for HIV-1 and HIV-2 protease[1].HIV protease is essential for release of mature viral and viral replication which is a retroviral aspartyl protease[2].

Saquinavir mesylate

A3791-5.1 10 mM (in 1mL DMSO)
EUR 146.4
Description: Saquinavir is a potent inhibitor HIV protease with Ki value of 0.12 and < 0.1 nM for HIV-1 and HIV-2 protease[1].HIV protease is essential for release of mature viral and viral replication which is a retroviral aspartyl protease[2].

Traxoprodil Mesylate

20-abx184454
  • EUR 1429.20
  • EUR 1813.20
  • 100 mg
  • 1 g

Deferoxamine mesylate

B6068-100 100 mg
EUR 129.6
Description: Deferoxamine mesylate is a specific iron-chelating agent [1][2][3]Deferoxamine mesylate can be used for treating acute iron intoxication. Deferoxamine complexed with iron to form ferrioxamine and then prevented the iron from entering into further chemical reactions.

Deferoxamine mesylate

B6068-500 500 mg
EUR 170.4
Description: Deferoxamine mesylate is a specific iron-chelating agent [1][2][3]Deferoxamine mesylate can be used for treating acute iron intoxication. Deferoxamine complexed with iron to form ferrioxamine and then prevented the iron from entering into further chemical reactions.

Sildenafil mesylate

B6073-25 25 mg
EUR 129.6
Description: IC50: 3.5 nMSildenafil mesylate is an inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).PDE5 is the predominant phosphodiesterase in the corpus cavernosum.

Sildenafil mesylate

B6073-50 50 mg
EUR 170.4
Description: IC50: 3.5 nMSildenafil mesylate is an inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).PDE5 is the predominant phosphodiesterase in the corpus cavernosum.

Sildenafil mesylate

B6073-500 500 mg
EUR 714
Description: IC50: 3.5 nMSildenafil mesylate is an inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).PDE5 is the predominant phosphodiesterase in the corpus cavernosum.

Bromocriptine mesylate

B6298-5.1 10 mM (in 1mL DMSO)
EUR 129.6

Bromocriptine mesylate

B6298-50 50 mg
EUR 236.4

Dihydroergocristine mesylate

B6313-100 100 mg
EUR 271.2

Dihydroergotoxine mesylate

B6327-100 100 mg
EUR 214.8

Dihydroergotoxine mesylate

B6327-50 50 mg
EUR 146.4

Tetrindole mesylate

B6419-10 10 mg
EUR 321.6

Tetrindole mesylate

B6419-50 50 mg
EUR 1167.6

Pirlindole mesylate

B6420-10 10 mg
EUR 240

Pirlindole mesylate

B6420-25 25 mg
EUR 489.6

Pirlindole mesylate

B6420-5 5 mg
EUR 154.8

Pirlindole mesylate

B6420-50 50 mg
EUR 870

Delavirdine mesylate

B1050-10 10 mg
EUR 166.8
Description: Delavirdine(U 90152) mesylate is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).

Delavirdine mesylate

B1050-100 100 mg
EUR 234
Description: Delavirdine(U 90152) mesylate is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).

Delavirdine mesylate

B1050-200 200 mg
EUR 363.6
Description: Delavirdine(U 90152) mesylate is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).

Delavirdine mesylate

B1050-5.1 10 mM (in 1mL DMSO)
EUR 180
Description: Delavirdine(U 90152) mesylate is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).

Delavirdine mesylate

B1050-50 50 mg
EUR 211.2
Description: Delavirdine(U 90152) mesylate is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).

Apilimod mesylate

B1129-25
EUR 652.8

Apilimod mesylate

B1129-5
EUR 210

Gatifloxacin mesylate

B1216-1000 1 g
EUR 166.8
Description: Gatifloxacin (mesylate) is an antibiotic of the fourth-generation fluoroquinolone family, it inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.

Gatifloxacin mesylate

B1216-5000 5 g
EUR 360
Description: Gatifloxacin (mesylate) is an antibiotic of the fourth-generation fluoroquinolone family, it inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.

Tigecycline mesylate

B1220-10 10 mg
EUR 254.4
Description: Tigecycline mesylate a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Tigecycline mesylate

B1220-100 100 mg
EUR 710.4
Description: Tigecycline mesylate a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Tigecycline mesylate

B1220-200 200 mg
EUR 970.8
Description: Tigecycline mesylate a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Tigecycline mesylate

B1220-50 50 mg
EUR 408
Description: Tigecycline mesylate a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Tigecycline mesylate

B1220-500 500 mg
EUR 1189.2
Description: Tigecycline mesylate a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Phentolamine Mesylate

B1363-100 100 mg
EUR 176.4
Description: Phentolamine Mesylate is a alpha 1- and alpha 2-blocking agent. Phentolamine leads to an increase in FBM by preferentially antagonizing presynaptic alpha 2-adrenoreceptors over postsynaptic alpha 1-adrenoreceptors. This influence of phentolamine on FBM ma

Phentolamine Mesylate

B1363-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Phentolamine Mesylate is a alpha 1- and alpha 2-blocking agent. Phentolamine leads to an increase in FBM by preferentially antagonizing presynaptic alpha 2-adrenoreceptors over postsynaptic alpha 1-adrenoreceptors. This influence of phentolamine on FBM ma

Phentolamine Mesylate

B1363-50 50 mg
EUR 153.6
Description: Phentolamine Mesylate is a alpha 1- and alpha 2-blocking agent. Phentolamine leads to an increase in FBM by preferentially antagonizing presynaptic alpha 2-adrenoreceptors over postsynaptic alpha 1-adrenoreceptors. This influence of phentolamine on FBM ma

Phentolamine Mesylate

B1363-S Evaluation Sample
EUR 97.2
Description: Phentolamine Mesylate is a alpha 1- and alpha 2-blocking agent. Phentolamine leads to an increase in FBM by preferentially antagonizing presynaptic alpha 2-adrenoreceptors over postsynaptic alpha 1-adrenoreceptors. This influence of phentolamine on FBM ma

Pergolide mesylate

B1485-2.5 2.5 mg
EUR 201.6
Description: Pergolide mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

Pergolide mesylate

B1485-5.1 10 mM (in 1mL DMSO)
EUR 362.4
Description: Pergolide mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

Pergolide mesylate

B1485-S Evaluation Sample
EUR 97.2
Description: Pergolide mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

Benztropine mesylate

B1554-5.1 10 mM (in 1mL DMSO)
EUR 129.6
Description: Benztropine is a dopamine transporter (DAT) inhibitor with IC50 of 118 nM.

Benztropine mesylate

B1554-50 50 mg
EUR 153.6
Description: Benztropine is a dopamine transporter (DAT) inhibitor with IC50 of 118 nM.

Benztropine mesylate

B1554-S Evaluation Sample
EUR 97.2
Description: Benztropine is a dopamine transporter (DAT) inhibitor with IC50 of 118 nM.

Trovafloxacin mesylate

B1565-25
EUR 940.8

Trovafloxacin mesylate

B1565-5
EUR 288

Apatinib mesylate

B1608-25
EUR 777.6

Apatinib mesylate

B1608-5
EUR 248.4

Ralfinamide mesylate

B7569-10 10 mg
EUR 388.8

Ralfinamide mesylate

B7569-50 50 mg
EUR 1453.2

Reboxetine mesylate

B2124-10 10 mg
EUR 166.8
Description: Reboxetine is a norepinephrine reuptake inhibitor with Ki of 8.2 nM.

Reboxetine mesylate

B2124-50 50 mg
EUR 517.2
Description: Reboxetine is a norepinephrine reuptake inhibitor with Ki of 8.2 nM.

Reboxetine mesylate

B2124-S Evaluation Sample
EUR 97.2
Description: Reboxetine is a norepinephrine reuptake inhibitor with Ki of 8.2 nM.

Pritelivir mesylate

B2154-25
EUR 548.4

Pritelivir mesylate

B2154-5
EUR 183.6

Ibutamoren mesylate

B2400-25
EUR 418.8

Talabostat mesylate